Trimodality Therapy for Malignant Pleural Mesothelioma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01343264|
Recruitment Status : Unknown
Verified April 2011 by HSK Wiesbaden.
Recruitment status was: Recruiting
First Posted : April 28, 2011
Last Update Posted : April 28, 2011
The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is still controversial. The selection criterion to perform either Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D) is dependent not only on the cardio-pulmonary status of the patient, tumor stage and intraoperative findings but also on surgeons' decision and philosophy. There are no established guidelines. Radical Pleurectomy (RP) competes against EPP as surgical therapy modality. Both surgical approaches are cytoreductive treatment options. The aim is to remove all gross disease and to achieve macroscopic complete resection.
Originally P/D was a palliative option for controlling pleural effusion. But lung-sparing surgery for MPM seems to be an alternative to patients unsuitable or unwilling to undergo EPP in a multimodality therapy concept. Most studies evaluating multimodality therapies for MPM are based on retrospective analyses and their interpretation is difficult because of inhomogeneous patient groups studied.
The aim of our study was to analyze the feasibility and results of RP as surgical therapy modality in a standardized trimodality therapy concept.
|Condition or disease|
|Malignant Pleural Mesothelioma|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy|
|Study Start Date :||November 2002|
|Estimated Primary Completion Date :||December 2012|
- To determine the overall 5-year survival rate. [ Time Frame: 5-years ]
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 3 months ]Morbidity
- Number of Participants with treatment related deaths as a Measure of Safety and Tolerability [ Time Frame: 3 months ]Mortality
- Recurrence [ Time Frame: 5 years ]Occurence of tumor recurrence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01343264
|Dr. Horst Schmidt Klinik, Department of Thoracic Surgery||Recruiting|
|Contact: Joachim Schirren, MD, PhD +49 611 433132 firstname.lastname@example.org|
|Principal Investigator: Joachim Schirren, MD, PhD|
|Sub-Investigator: Servet Bölükbas, MD, PhD|
|Principal Investigator:||Joachim Schirren, MD, PhD||HSK Wiesbaden|